Patents have been filed and don't infringe on others (i.e. there...

Patents have been filed and don't infringe on others (i.e. there are none and the one Pfizer had expired). Big Pharma are aware of LTP and its innovation with no objections to date. We are in fact selling product now so if someone thought we were infringing their patent, we would know about it. The FDA will also give LTP 3years exclusivity in the market once they approve the drug.

See a good extract on this topic from https://www.livewiremarkets.com/wires/ltr-pharma-ed-the-need-for-speed

"IP & Patents & Market ExclusivityInvestors should look to the Patent Report in the prospectus as it relates to Spontan (page 103 of the Prospectus). Patent strategies are bespoke and highly specialised. I am not an expert so we sought to corroborate LTP's patents and approach with patent lawyers, and we were happy with their views. The research group SDS prosecute the patents, on LTP's behalf, as the inventor, and it is often a strategy to delay and hinder potential competition as you look to protect your IP. If you were thinking of raising funds to develop a competing intranasal spray, the fact these patents are lodged would make it difficult to get funding. Companies will often start with broad claims, which can be rejected, and they will then refine them. It is normal for a claim to be rejected, refined and re-submitted. It's a multi-year process. Companies have protection in jurisdictions whilst patents are pending. Companies buy themselves time within the limitations of the patent process.LTP has taken the common path of securing a global licensing deal with the inventor SDS, and LTP has the global rights to Spontan. Also, any patent granted to SDS is legally then transferred to LTP.It is also a double-edged sword for research groups like SDS, if the patent application reveals exactly how they got the formulation to work, competitors in non-patent-protected jurisdictions can get to work on your IP. In a global market for ED, you protect the “secret sauce” for as long as practical, and protect against a black market replica of your drug.If Spontan is approved, the FDA will give the drug exclusivity to market for 3 years, under the 505(b)(1) and 505(b)(2) NDA pathways. This additional advantage will prevent a competitor's nasal spray from using vardenafil for 3 years in the US".

DYOR.